Mecamylamine
Inversine (mecamylamine) is a small molecule pharmaceutical. Mecamylamine was first approved as Inversine on 1982-01-01. It is used to treat malignant hypertension and tourette syndrome in the USA. The pharmaceutical is active against neuronal acetylcholine receptor subunit alpha-3. In addition, it is known to target neuronal acetylcholine receptor subunit alpha-4, neuronal acetylcholine receptor subunit alpha-2, acetylcholine receptor subunit alpha, neuronal acetylcholine receptor subunit alpha-6, and neuronal acetylcholine receptor subunit alpha-7.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mecamylamine hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
INVERSINE | Catalyst Biosciences | N-010251 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
malignant hypertension | EFO_1001031 | D006974 | — |
tourette syndrome | EFO_0004895 | D005879 | F95.2 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/trials-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
Glioblastoma | D005909 | EFO_0000515 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | MECAMYLAMINE |
INN | mecamylamine |
Description | Mecamylamine (INN, BAN; or mecamylamine hydrochloride (USAN); brand names Inversine, Vecamyl) is a non-selective, non-competitive antagonist of the nicotinic acetylcholine receptors (nAChRs) that was introduced in the 1950s as an antihypertensive drug. In the United States, it was voluntarily withdrawn from the market in 2009 but was brought to market in 2013 as Vecamyl and eventually was marketed by Turing Pharmaceuticals.
|
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CNC1(C)C2CCC(C2)C1(C)C |
Identifiers
PDB | — |
CAS-ID | 60-40-2 |
RxCUI | — |
ChEMBL ID | CHEMBL267936 |
ChEBI ID | 6706 |
PubChem CID | 4032 |
DrugBank | DB00657 |
UNII ID | 6EE945D3OK (ChemIDplus, GSRS) |
Target
Agency Approved
CHRNA3
CHRNA3
Organism
Homo sapiens
Gene name
CHRNA3
Gene synonyms
NACHRA3
NCBI Gene ID
Protein name
neuronal acetylcholine receptor subunit alpha-3
Protein synonyms
cholinergic receptor, nicotinic alpha 3, cholinergic receptor, nicotinic, alpha 3 (neuronal), cholinergic receptor, nicotinic, alpha polypeptide 3, neuronal nicotinic acetylcholine receptor, alpha3 subunit
Uniprot ID
Mouse ortholog
Chrna3 (110834)
neuronal acetylcholine receptor subunit alpha-3 (Q8R4G9)
Alternate
CHRNA4
CHRNA4
CHRNA2
CHRNA2
CHRNA1
CHRNA1
CHRNA6
CHRNA6
CHRNA7
CHRNA7
Organism
Homo sapiens
Gene name
CHRNA4
Gene synonyms
NACRA4
NCBI Gene ID
Protein name
neuronal acetylcholine receptor subunit alpha-4
Protein synonyms
cholinergic receptor, nicotinic alpha 4, cholinergic receptor, nicotinic, alpha 4 (neuronal), cholinergic receptor, nicotinic, alpha polypeptide 4, neuronal nicotinic acetylcholine receptor alpha-4 subunit
Uniprot ID
Mouse ortholog
Chrna4 (11438)
neuronal acetylcholine receptor subunit alpha-4 (Q9ET51)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-terms-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,047 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-adverse-reactions-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
576 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more